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Abstract
Background: Cerebral small vessel disease (SVD) is a frequent finding on CT and MRI scans of elderly people and is
related to vascular risk factors and cognitive and motor impairment, ultimately leading to dementia or parkinsonism in
some. In general, the relations are weak, and not all subjects with SVD become demented or get parkinsonism. This
might be explained by the diversity of underlying pathology of both white matter lesions (WML) and the normal
appearing white matter (NAWM). Both cannot be properly appreciated with conventional MRI. Diffusion tensor imaging
(DTI) provides alternative information on microstructural white matter integrity. The association between SVD, its
microstructural integrity, and incident dementia and parkinsonism has never been investigated.
Methods/Design: The RUN DMC study is a prospective cohort study on the risk factors and cognitive and motor
consequences of brain changes among 503 non-demented elderly, aged between 50-85 years, with cerebral SVD.
First follow up is being prepared for July 2011. Participants alive will be included and invited to the research centre
to undergo a structured questionnaire on demographics and vascular risk factors, and a cognitive, and motor,
assessment, followed by a MRI protocol including conventional MRI, DTI and resting state fMRI.
Discussion: The follow up of the RUN DMC study has the potential to further unravel the causes and possibly
better predict the consequences of changes in white matter integrity in elderly with SVD by using relatively new
imaging techniques. When proven, these changes might function as a surrogate endpoint for cognitive and motor
function in future therapeutic trials. Our data could furthermore provide a better understanding of the
pathophysiology of cognitive and motor disturbances in elderly with SVD. The execution and completion of the
follow up of our study might ultimately unravel the role of SVD on the microstructural integrity of the white
matter in the transition from “normal” aging to cognitive and motor decline and impairment and eventually to
incident dementia and parkinsonism.
Background
Cerebral small vessel disease (SVD) includes white matter
lesions (WML) and lacunar infarcts and is a frequent find-
ing on computer tomography (CT) and magnetic reso-
nance imaging (MRI) scans of elderly people [1]. It is
associated with vascular risk factors, such as hypertension,
atherosclerosis, diabetes mellitus and atrial fibrillation
[2-4]. In cerebral SVD symptoms are due to either com-
plete (lacunar syndromes) or incomplete infarction
(WML) of subcortical structures leading to accompanying
complaints including the lacunar syndromes, cognitive,
motor (gait) and/or mood disturbances [5]. The preva-
lence of WML and lacunar infarcts varies considerably
across studies from 5-95% and 8-28% respectively,
depending on the population studied and the imaging
technique used [1,6]. There is evidence of an increased
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bances and parkinsonism among individuals with SVD,
although prospective studies are scarce [7-10].
However, individuals with a virtually identical WML
burden on conventional FLuid Attenuated Inversion
Recovery (FLAIR) imaging present with a wide variance
in cognitive and motor performance ranging from no
complaints at all to subjective cognitive complaints and
mild parkinsonian signs to dementia and parkinsonism.
Apparently there are other factors that determine
whether identical appearing WML on FLAIR lead to for
example cognitive or motor decline in one person, while
leaving others unaffected.
One of the other factors could be the presence the
coexisting manifestations of cerebral SVD on conven-
tional MRI such as lacunar infarcts and cerebral micro-
bleeds which might influence the cognitive and motor
performance [11].
As identical appearing WML on conventional MRI are
actually histopathologically heterogeneous [12], it could
be that only the WML with a high loss of microstruc-
tural integrity are related to cognitive and motor impair-
ment. It is also important to realize that only a small
proportion of the white matter (usually less than a few
percent) is affected by SVD, even among individuals
with severe SVD [13]. As conventional MRI is not sensi-
tive to early loss of microstructural integrity in the nor-
mal appearing white matter (NAWM), possible changes
in this largest part of the white matter cannot be
assessed [14,15]. These limitations of conventional MRI
can potentially be overcome with the use of Diffusion
Tensor Imaging (DTI) which allows us to assess the
microstructural integrity of the whole white matter [16].
DTI, amongst others, provides two parameters; mean
diffusivity (MD), a measure of the magnitude of diffu-
sion of water in the white matter, and fractional aniso-
tropy (FA), which provides information about the
directionality of water diffusion. Damage to the white
matter is supposedly accompanied roughly by an
increase in MD and a decrease in FA [17].
Another explanation for the clinical diversity due to
WML could be the efficiency of compensation mechan-
isms that prevent further cognitive and motor (gait) dete-
rioration. Support for the existence of compensatory
mechanisms comes from a study among young carriers of
a pre-senilin mutation (at risk for genetically determined
Alzheimers’ disease (AD), but still without cognitive
impairment) who showed altered functional connectivity
(assessed with fMRI) compared with controls [18]. With
innovative resting state fMRI techniques the strength of
functional connectivity between brain regions can be
investigated [19]. In that way it might be that these com-
pensation mechanisms also play a role in the variety of
clinical presentation of individuals with SVD.
In the RUN DMC (Radboud University Nijmegen Dif-
fusion tensor and Magnetic resonance imaging Cohort)
study we prospectively investigate the effect of SVD on
the transition from non-demented, independently living
elderly people with cerebral SVD between 50 and 85
years towards cognitive and motor (gait) decline, and
ultimately dementia and parkinsonism in a population
with cerebral SVD. The primary objective of the RUN
DMC study is to prospectively investigate the risk fac-
tors for and cognitive and motor (gait) consequences of
longitudinal functional and structural changes in the
integrity of the cerebral white matter as assessed by
DTI, resting state fMRI and conventional structural
MRI. To the best of our knowledge there are no other
prospective cohort studies investigating the development
of incident dementia and parkinsonism using these
novel imaging techniques. Here we describe the study
design and protocol of the RUN DMC study.
Methods/Design
Study population
Cerebral SVD is characterized on neuroimaging by either
WML or lacunar infarcts. Symptoms of SVD include
acute symptoms, such as transient ischemic attack (TIA)
or lacunar syndromes, but also subacute manifestations
such as cognitive and motor (gait) disturbances [5]. As
the onset of cerebral SVD is often insidious, clinically
heterogeneous, and typically with mild symptoms, it has
been suggested that the selection of subjects with cere-
bral SVD in clinical studies should be based on the more
consistent brain imaging features [20].
Accordingly, in 2006, consecutive individuals referred
to the Department of Neurology between October 2002
and November 2006, were selected for possible partici-
pation. Inclusion criteria were: (a) age between 50 and
85 years; (b) cerebral SVD on neuroimaging (WML and/
or lacunar infarcts). Subsequently, the above mentioned
acute and subacute clinical symptoms of SVD were
assessed by standardized structured assessments (a ques-
tionnaire for TIA and stroke [21]; for cognition the Cog-
nitive Failures Questionnaire [22]; for gait the Falls
Questionnaire [23] and the Freezing of Gait Question-
naire [24]) Subjects who were eligible because of a lacu-
nar syndrome were included only > 6 months after the
event to avoid acute effects on the outcomes.
To be able to detect incident dementia and parkinson-
ism we applied the following exclusion criteria: (a) pre-
sence of dementia [25] and (b) parkinson(-ism)[26,27]. In
addition patients with (c)intracranial hemorrhage; (d) life
expectancy of less than six months; (e) intracranial space
occupying lesion; (f) (psychiatric) disease interfering with
cognitive testing or follow-up; (g) recent or current use
of acetylcholine-esterase inhibitors, neuroleptic agents,
L-dopa or dopa-a(nta)gonists; (h) non-SVD related WML
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impairment; (j) language barrier; (k) MRI contraindica-
tions or known claustrophobia were excluded.
All participants signed an informed consent form. The
Medical Review Ethics Committee region Arnhem-
Nijmegen approved the study.
Follow-up
After 5 and 10 years all participants alive will be con-
tacted for the prospective assessment of possible out-
come events. This evaluation is currently being prepared
for July 2011.
Between 2006 and 2011 we contacted all participants
every year by letter for an update on their address informa-
tion and telephone number and for their survival status.
In 2011 all participants alive will be invited by letter
and subsequently contacted by telephone to visit our
research centre. During their visit to the research centre
a cognitive, gait, balance and parkinsonian signs assess-
ment, a structured interview, physical examination,
neurological examination, and an extensive MRI proto-
col, an electrocardiogram and an ultrasonography of the
carotid arteries will be performed. All tests will be
performed by the same two trained neurology residents
and all MRI scans will take place on the same scanner.
Outcome events
Primary measures of outcome of the study are incident
dementia and parkinsonism according to international
diagnostic criteria [25,27], as well as all-cause mortality
and death from all vascular causes, non-fatal stroke, and
non-fatal myocardial infarction.
Secondary outcome measures are defined as change
from baseline examination in cognitive function, gait
and balance and parkinsonian signs.
Incident outcome events are to be identified by three
different approaches.
1. During the follow-up a structured questionnaire on
the possible occurrence on these outcome events is
administered to each participant. When an incident
event is suspected the treating physician will be con-
tacted for the most recent information on that particular
outcome event.
2. When a participant died before follow-up, the gen-
eral practitioner will be contacted for the most recent
information on the cause of death and presence of pri-
mary outcome events. In case of presence of primary
outcome events the treating physician will be contacted
for the most recent information available.
3. When during follow-up assessment participants’ test
results are suggestive for incident dementia or parkinson-
ism, subjects will be referred to our outpatient clinic. In
case the diagnosis is established according to the interna-
tional criteria, this will be considered an incident case.
All outcome events will be adjudicated independently
by two specialised physicians, if the two classifications
differ, the outcome event will be discussed and consen-
sus will be made.
Assessment of cognitive and motor outcomes
Two trained residents in neurology will administer the
complete outcome assessment.
Cognitive assessment
We will use an extensive neuropsychological test battery
that encompasses items from other large scale epidemio-
logical studies that cover virtually all cognitive domains
[10,28]. A measurement of global cognitive function will
be assessed by the Mini Mental State Examination
(MMSE) [29]. The verbal memory function will be
assessed by the three-trial version of the Rey Auditory
Verbal Learning Test (RAVLT), a test used to evaluate
the ability to acquire and retain new verbal information
[30]. Visuospatial memory will be administered by the
Rey’s Complex Figure Test (RCFT), that consists of three
subtasks: the copy trial, the immediate recall trial, within
3 minutes and the delayed recall trial, after 30 minutes
[31]. To evaluate speed of mental processes four tests
will be used; the Stroop test (three subtasks) [32], the
Paper and Pencil Memory Scanning Task (four subtasks)
[33], the Symbol-Digit Substitution Task, which is a
modified version of the Symbol Digit Modalities Test
[34] and a verbal fluency task in which as many animals
as possible have to be named within 60 seconds, followed
by as many professions within 60 seconds. To evaluate
attention, the verbal series attention test (VSAT) will be
used [35]. To register subjective cognitive failures we will
administer the Cognitive failures questionnaire (CFQ)
[22]. The tests will be carried out in quiet rooms and a
stopwatch will be used in timed tests.
Assessment of gait, balance and parkinsonian signs
All participants will perform a tandem walk by walking
ten steps heel to toe (registering: intact, one side step,
more side steps, impossible). A quantitative gait analysis
will be performed with a 5.6-meter long, 0.89-meter
wide electronic walkway (GAITRite
® MAP/CIR Inc.,
Havertown, PA) with sensor pads (12.7 mm apart from
each other) connected to a computer. This system has
strong concurrent validity and test-retest reliability, also
in older people [36]. The participants walk twice at self-
selected gait speed on low-heeled shoes. They start two
meters before the carpet and walk until two meters
behind it in order to measure steady-state walking.
We will use a widely used modified version of the original
Tinetti test with 17 items: 9 for body balance (score 0-16)
and 8 for gait (score 0-12), with a maximum score of
28 [37]. It grades balance while sitting, standing with eyes
open and closed, nudging and turning, gait initiation, stride
length and width and symmetry. Functional mobility will
van Norden et al. BMC Neurology 2011, 11:29
http://www.biomedcentral.com/1471-2377/11/29
Page 3 of 8be classified by using the widely-used TUG-test which is a
timed test during which the participant is asked to rise
from a standard armchair, walk 3 m, turn, walk back and
sit down again [38]. Each participant will perform the test
three times. To evaluate parkinsonian signs we apply the
Unified Parkinson’s Disease Rating Scale (UPDRS), the
motor score [39]. Finally disease severity will be assessed
with the Hoenhn and Yahr stage assessing [40]. For the
evaluation of gait and balance we will also administer the
Freezing of gait questionnaire (FOG), a questionnaire con-
sisting of 16 items regarding gait and falls and the Falls
questionnaire [23,24].
Assessment of activities of daily living
As a measure of disability the Barthel Index will be used
[41]. The activities of daily living will be assessed by the
instrumental activities of daily living questionnaire [42].
Structured interview
Demographics and life style Standardized question-
naires on demographics, education (classified using 7 cate-
gories, 1 being less than primary school and 7 reflecting
an academic degree)[43], marital status, living conditions,
and life style habits (alcohol consumption, smoking, exer-
cise) will be administered. Alcohol consumption is defined
as units per day and the age at which alcohol consumption
had started (and if stopped) was noted. Cigarette smoking
behaviour is defined as the number of pack-years, calcu-
lated as the number of packs of cigarettes smoked per day
multiplied by the number of years a participant had
smoked. Exercise is expressed in the metabolic equivalent
value (MET) according to accepted standards, where
1 MET is proportional to the energy expended while sit-
ting quietly [44].
Vascular risk factors and cardiovascular disease With
the aid a of structured, standardized questionnaire each
participant will be asked for a history of: hypertension, dia-
betes mellitus, atrial fibrillation, TIA, stroke, myocardial
infarction, coronary artery bypass graft, per-cutaneous
transluminal coronary angiography, aortic prothesis,
vascular prothesis, carotid endartectomy [2-4,21] and
migraine [45] The presence of a family history of myocar-
dial infarction, cerebrovascular disease and diabetes
mellitus in next of kin will be recorded.
Current medication Current medication use will be
noted and classified according to the Anatomical thera-
peutic chemical (ATC) classification system. (World
Health Organization, WHO Collaborating Centre for
drug statistics and methodology, http://www.whocc.no/
atcddd/)
Assessment of other variables
Depressive symptoms
A standardized structured questionnaire used in pre-
vious large scale epidemiological studies will be used to
assess for the history of depressive symptoms; normal
reactions to stressful events or normal grief will carefully
be excluded [46]. In case of a depressive episode, age of
onset, the medical advice and medication use will be
registered. We defined ‘depression’ as those depressive
episodes that have required attention of a general practi-
tioner, psychologist, or psychiatrist. This definition
includes minor depression, as well as more severe
depression syndromes such as major depression and
bipolar depression [46].
In addition participants will be screened for depressive
symptoms by means of the Mini International Neurop-
sychiatric Interview (MINI), part A, which is a short
diagnostic structured interview based on the DSM IV
[47]. Additionally, presence of actual depressive symp-
toms will be assessed by two self report questionnaires,
the Center of Epidemiologic Studies Depression Scale
(CES-D) [48] and the Hospital Anxiety and Depression
Scale (HADS) [49].
Additional Self-report questionnaires
For the assessment of sleep disorders we will use the
SCOPA-Sleep scale [50] and for fatigue the Checklist on
Individual Strength (CIS20R) [51]. The overall health
status (quality of life) will be assessed with the Short
Form 36 (SF-36) [52,53].
Physical Examination
Height and weight will be measured without shoes in
light clothing. The body mass index (BMI) is calculated
as weight divided by height (in meters) squared. The
maximal waist circumference will be measured without
shirt, in standing position, between the lowest rib and
the iliac crest, at the end of normal expiration [54].
Blood pressure and pulse rate will be measured in tripli-
cate in supine position after 5 minutes rest. Subse-
quently one measurement is performed after 1 minute
in upright position [3].
Neurological examination
Primary reflexes The presence of the glabella, snout
and grasp reflex, the applause sign [55] and the plantar
response will be registered.
Muscle strength The strength of the biceps, hand grip,
iliopsoas, quadriceps and foot extensor muscles on both
sides will be measured by the medical research council
scale (MRC) and by a dynamometer. (Citec
® hand-held
dynamometer) [56].
Sensory system will be assessed by a quantitative mea-
surement by vibration tuning fork (Rydel-Seiffer
®)o n
both first toes and both medial malleolus, also register-
ing ankle oedema and ankle jerks.
Ancillary Investigation
MRI protocol
MRI scanning will be performed on a 1.5-Tesla Magnetom
scanner (Siemens, Erlangen, Germany). The scanning pro-
tocol includes whole brain 3 D T1 magnetization-prepared
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2250/3.68/850ms; flip angle 15°; voxel size 1.0 × 1.0 × 1.0
mm); FLAIR pulse sequences (time repetition [TR]TE/TI
9000/84/2200 ms; voxel size 1.0 × 1.2 × 6.0 mm (including
slice gap of 1 mm); transversal T2* weighted gradient echo
sequence (TR/TE 800/26 ms; voxel size 1.3 × 1.0 × 6.0 mm
(including slice gap of 1.0 mm); DTI (TR/TE 10100/93ms;
voxel size 2.5 × 2.5 × 2.5 mm; 4 unweighted scans, 30 dif-
fusion weighted scans, with non co-linear orientation of
the diffusion-weighting gradient, and b value 900 s/mm
2)
and resting state imaging using a gradient echo EPI
(TR/TE 2400/40ms; voxel size 3.5 × 3.5 × 4.4 mm (includ-
ing slice gap of 0.4 mm)). During resting state, subjects will
be told not to concentrate on any particular subject, but
just to relax with their eyes closed. The complete scanning
protocol takes 31 minutes.
White matter lesions All images will be evaluated with-
out prior notice of any clinical parameter. WML are
defined as hyperintense lesions on FLAIR MRI without
corresponding cerebrospinal fluid like hypo-intense
lesions on the T1 weighted image. Gliosis surrounding
lacunar and territorial infarcts is not considered to be
WML [57]. Total WML volume is calculated by an in-
house developed, validated technique.
Brain volumetry Normalization parameters to the
ICBM152 linear template (as provided with SPM5; Well-
come Department of Cognitive Neurology, University
College London, UK) and gray and white matter tissue
and cerebrospinal fluid probability maps is computed by
using SPM5 unified segmentation routines on the T1
MPRAGE images [58]. Total grey and white matter
volumes are calculated by summing all voxel volumes
that have a p > 0.5 for belonging to the tissue class. Total
brain volume is taken as the sum of total grey- and total
white matter volume. Co-registration parameters of the
FLAIR image to the T1 image are computed (SPM5
mutual information co-registration) and used to bring
both the FLAIR and WML segmentation images into the
subject’s (anatomical) reference frame. Transformed
images will visually be checked for co-registration errors.
Subsequently, the WML segmentations are resampled to
and combined with the white matter maps to yield to a
WML map (the intersection of WML and white matter)
and NAWM map (the complement of WML in white
matter) in the T1 reference space. Total brain volume is
taken as the sum of total gray and white matter.
Lacunar and territorial infarcts Lacunar infarcts are
defined as hypo-intense areas > 2 mm and ≤ 15 mm on
FLAIR and T1, ruling out enlarged perivascular spaces
(≤ 2 mm, except around the anterior commissure,
where perivascular spaces can be large) and infraputam-
inal pseudolacunes [57]. Territorial infarcts are defined
as hyperintense lesions on FLAIR and hypointense
lesions on T1 images >15 mm [57].
Microbleeds Microbleeds are defined as small, homoge-
neous, round foci of low signal intensity on T2*
weighted images of less than 10 mm in diameter [59].
Microbleeds are counted per hemisphere separately. In
addition they are classified as cortical/subcortical includ-
ing the periventricular white matter and deep portions
of the centrum semiovale (frontal, parietal, occipital and
temporal separately); in the basal ganglia, including cau-
date nucleus, internal and external capsule, globus palli-
dus, thalamus and putamen; infratentorial including the
cerebellar hemispheres, pons and medulla oblongata
[59]. Lesions are not considered to be microbleeds when
they are symmetric hypointensities in the globus palli-
dus, most likely calcifications or iron deposits, flow
voids artifacts of the pial blood vessels or hyposignals in
T2* inside a lesion compatible with an infarct, likely to
be hemorrhagic transformation [59].
Diffusion tensor imaging The diffusion weighted images
of each participant are realigned on the unweighted
image using mutual information based Matlab (The
Mathworks, Inc.) routines from SPM5. Then, the diffu-
sion tensor and its eigenvalues are computed using an
SPM5 add-on http://sourceforge.net/projects/spmtools
[60]. Unphysical spurious negative eigenvalues of the
diffusion tensor were set to zero, after which the tensor
derivatives the FA and MD are calculated [61]. The mean
unweighted image is used to compute the co-registration
parameters to the anatomical T1 image (SPM5 mutual
information co-registration), which are then applied to
all diffusion weighted images and results. All images are
visually checked for motion artefacts and coregistration
errors.
Electrocardiogram
An electrocardiogram (ECG) will be performed and
evaluated by a standardized assessment by an experi-
enced cardiologist, registering frequency, cardiac
rhythm, cardiac ectopias, cardiac axis, conduction time
over the PQ, QRS and QTC intervals, conduction dis-
turbances, left ventricle hypertrophy, pathologic Q’s,
infarction, repolarisation disturbances and acute ische-
mia. A final diagnosis is defined as normal, abnormal
without clinical significance, abnormal with clinical con-
sequences or pathologic ECG with immediate consulta-
tion of a cardiologist when necessary.
Ultrasonography of the carotid arteries
All ultrasound measurements will be performed by three
experienced and specific trained clinical neurophysiology
technicians. A carotid ultrasound assessment at which
the intima media thickness (IMT) is measured in the
distal left and right carotis communis, near the bulbus,
will be performed. All measurements will be performed
using a phased array real-time scanner (Philips i-u22,
van Norden et al. BMC Neurology 2011, 11:29
http://www.biomedcentral.com/1471-2377/11/29
Page 5 of 8The Netherlands) with a 17-5 MHz broadband linear
transducer. Two-dimensional ultrasound imaging of the
carotid artery will be performed to measure the IMT.
The IMT will be automatically measured by QLab
® qua-
lification software (V. 4.2.1.). An edge detection algo-
rithm identified the lumen/intima and the media/
adventitia interfaces within a region of interest over a
10 mm long segment and calculated the average thickness
[62].
The same cognitive, motor, gait and balance assess-
ment, structured interview and assessment of other vari-
ables and the same ancillary investigation were
performed at baseline in 2006.
Statistical analysis
Sample size calculation
Based on the literature we expect about 60 incident
dementia cases during the five year follow up (absolute
risk 4-5%/year), as about half of our study population
has a relatively high degree of WML [63]. We expect
that each SD increase in MD increases this absolute risk
of dementia by 2% per year. To detect this increased
risk with a high probability of 90% at the 5% significance
level we will need 380 participants at the end of the fol-
low up, so therefore we included 500 participants at
baseline and hope to end up with 400 participants at
follow-up protocol (taking into account an expected loss
to follow up of about 20%).
Analysis of primary outcome measures
We will analyze mean baseline MD and FA and change
in MD and FA on follow up imaging in relation to inci-
dent dementia and parkinsonism by Cox proportional
hazard models adjusted for age, sex, education, depres-
sive symptoms, total brain volume, white matter lesion
volume and lacunar infracts, where appropriate.
Discussion
The RUN DMC study is a large prospective cohort
study on causes and consequences of structural and
functional changes in the integrity of the cerebral white
matter (in both the WML and the NAWM) as assessed
by conventional MRI as well as new techniques, such as
DTI and resting state fMRI, among elderly with cerebral
SVD, starting to include participants for the follow-up
protocol in July 2011.
Numerous studies have shown that WML observed on
conventional MRI are related to vascular risk factors
and have reported associations with cognitive and motor
decline and found these relations to be rather weak
[3,4,8,10,46]. To the best of our knowledge there are no
prospective cohort studies on individuals with cerebral
SVD investigating the development of incident dementia
and parkinsonism in relation to white matter changes
assessed by DTI and resting state fMRI.
Strengths of the RUN DMC study include the pro-
spective fashion of the study in which all vascular risk
factors, clinical and imaging measures will be followed
up after five years, and the large and well-established
protocol used to explore demographics, vascular risk
factors, and cognitive and motor function. The tests
chosen are furthermore widely accepted and have been
proven specific and sensitive in this population with
structural brain changes.
Another strength is the fact that it is a single centre
study. Moreover, the complete study protocol will take
place in one research centre with the use of a single
scanner and only two investigators performing all
investigations.
In conclusion, the RUN DMC study has the potential
to further unravel the causes and consequences of
changes in white matter integrity in elderly with cerebral
SVD by using new imaging techniques, DTI and resting
state fMRI. When proven, changes in white matter integ-
rity assessed by these techniques might function as a sur-
rogate endpoint for cognitive and motor function in
future therapeutic trials of vascular risk factors in SVD.
The execution and completion of the follow-up of our
study will ultimately unravel the role of SVD on the
microstructural integrity of the white matter in the tran-
sition from “normal” aging to cognitive and motor
decline and impairment and eventually to incident
dementia and parkinsonism.
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